Efficacy of sodium glucose cotransporter 2 inhibitors for heart failure with preserved and mildly reduced ejection fraction: a systematic review and meta-analysis

1 December 2022 (13:00 - 18:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Kathleen Rivera

Philippine Heart Center, Manila (Philippines)

27 More presentations in this session

Presentation thumbnail

Frequent need for apixaban dose adjustment for atrial fibrillation in an unselected acute medical admission population during the COVID 19 pandemic.

Doctor K. Kyaw (Plymouth, GB)

Abstract Slides

Presentation thumbnail

The use of hatch score for the prediction of post operative atrial fibrillation (poaf) after coronary artery bypass graft: a meta-analysis

Doctor A. Ramos (Muntinlupa, PH)

Abstract Slides

Presentation thumbnail

Relationship and outcomes between volume status, cardiac and renal dysfunction in patients with chronic heart failure.

Doctor A. Challa (Rochester, US)

Abstract Slides

Presentation thumbnail

Association between triglyceride and all-cause mortality and cardiovascular outcomes in heart failure patients: a territory-wide study in Hong Kong

Mrs Q. Ren (Hong Kong, HK)

Abstract Slides

Presentation thumbnail

Effects of SGLT2 inhibitors on heart failure symptoms, quality of life and exercise capacity in patients with heart failure and preserved ejection fraction: A meta-analysis

Doctor L. Merin (Cebu City, PH)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 1

The Event

Event poster

ESC Asia 2022 with APSC & AFC

1 December 2022 13:00 CET

You may be interested in

Congress Presentation

Audience Q&A

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

Congress Session

Which device might help your HFpEF patient?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources